Thermo Fisher and the jellyfish gene sign a core strategic cooperation agreement involving gene chip analysis and second generation sequencing
It was learned that Beijing Jellyfish Technology Co., Ltd. (hereinafter referred to as “Jellyfish Geneâ€), a leader in the domestic consumer-grade genetic testing industry, and the world leader in scientific services, Thermo Fisher Scientific (hereinafter referred to as “Simoâ€) jointly announced: The two sides have reached a "core strategic partnership", and will carry out extensive and in-depth cooperation in the field of genetic testing in the future to promote the development of China's mass genetic testing, thereby promoting the development of the health industry.
Signing Ceremony: Marc Casper, President and CEO of Thermo Flying Global, and Tony Acciarito, President of Thermo Fisher China, and Dr. Zhao Nan, CEO of Jellyfish Gene & Dr. Zhao Nan
The achievement of the core strategic partnership between Jellyfish Gene and Thermo Fisher has marked a new phase of cooperation: the jellyfish gene will introduce Ion GeneStudio TM in addition to the introduction of Thermo Fisher Scientific's complete gene chip analysis system. S5 Plus second generation sequencing platform technology. The jellyfish gene will be localized based on this. It will be developed and produced in China, and the localization equipment will be launched for clinical testing centers of various medical institutions to conduct in vitro diagnosis of clinical microbial direction, and the genetic test data will be integrated with clinical data to reflect more comprehensively. The health status of the subject.
In addition, the jellyfish gene will also carry out research and development and registration of kits on the Ion GeneStudio TM S5 Plus platform according to clinical needs. A series of clinical diagnostic products for different microorganisms will be launched. This also means that the jellyfish gene has further expanded its gene sequencing capabilities and has taken a solid step in the field of personal health data management.
Ion GeneStudio TM S5 Plus Second Generation Sequencing Platform
According to statistics, by 2020, the overall size of China's health market will exceed 1.2 trillion US dollars. Genetic testing technology, as the cornerstone of the future precision medical field, has naturally received widespread attention from the government and capital markets. Recently, the Chinese government announced the "Application of the Second Batch of Gene Detection Technologies", which shows the government's emphasis on this market. Based on the pre-judgment of the huge amount of China's consumer-grade genetic testing market in the future, and Thermo Fisher's powerful bio-detection technology research and development capabilities, the jellyfish gene was first established in the Yiwu Economic Development Zone in September, covering an area of ​​nearly 5,000 square meters. The Global Innovation Demonstration Center for Gene Detection Technology, which will focus on the application scenarios of genetic testing technologies and the stability and accuracy of detection technologies.
It is understood that the current jellyfish gene mainly uses the Thermo Scientific Applied Biosystems Gene Chip Analysis System (GeneTitan TM ), combined with the Ion Torrent second-generation sequencing technology platform, and on this basis, continuously guide and launch more targeted genes. Detect service products. In the upcoming cooperation between the two parties, Thermo Fisher will dock the technical team of the jellyfish gene R&D department to support its product development, relying on the leading industry position of the jellyfish gene and strong marketing ability to quickly and accurately launch a large and suitable Chinese consumer. Health products.
Senior officials from both sides attended and witnessed this important ceremony
In the face of the upcoming in-depth cooperation, Tony Acciarito, President of Thermo Fisher China, said: “China is one of the most important markets for Thermo Flying. This cooperation with Jellyfish shows our localization strategy. Fruitful results. We will continue to work with local customers to help our customers make China healthier, cleaner and safer."
In recent years, the advancement of genetic testing technology and the reduction of prices have made the heat of genes constantly refreshed on a global scale. In 2018, the UK announced that it would sequence and decode the genome of 5 million Britons to create the world's largest health database. As of 2017, 830,000 people in 140 countries around the world have participated in the “gene geography engineering†in the United States; the ancestral DNA testing kits have sold more in the US market, with total sales exceeding 6 million. Intestinal flora and microbial detection is one of the most popular fields in the international scientific research field in recent years, and its related research results often occupy the cover of "Nature", "Science" and "Cell" magazine.
Dr. Zhao Nan, Chief Scientist of Jellyfish Gene, has an in-depth exchange with Marc Casper, President and CEO of Thermo Fisher
At present, the jellyfish gene has five core products, “Life Coach·Personal Genome Detectionâ€, “Life Map, Zuyuan+Health Personal Genome Detectionâ€, and “Jellyfish Cloud·Enterprise Serviceâ€, which can provide genetic testing for different populations. Personalized health guidance. With the market prospect for genetic testing, Mr. Wang Xiaokang, founder and CEO of Jellyfish, is full of confidence. He said: "China's genetic testing is currently the most widely used in the medical field, such as prenatal testing, which has reached millions of cases every year. However, in areas other than medical care, development has been relatively advanced. On the technical level Look, whether it is detection accuracy or cost control, the technology of genetic testing is quite mature, and its commercial value and application scenarios will be very extensive."
Speaking of the cooperation with Thermo Fisher, Wang Xiaokang said: "Scientific research is the cornerstone of the healthy development of the industry. The jellyfish gene is facing the future and is committed to continuous efforts to further consolidate its research and development capabilities, to meet medical standards, and to provide the public with More professional, rigorous, fast and efficient service. The establishment of a core strategic partnership with Thermo Fisher will have a positive impact on research and technology applications in the field of health. The jellyfish gene will be based on the Ion GeneStudio TM S5. The introduction of the Plus platform, the introduction of high-quality, high-coverage gene sequencing services and products, enabling Chinese consumers to benefit from more products that meet national conditions, meet the individual needs of consumers, and genetic testing and clinical microbiological testing. The entire health industry."
The frequency of the ultrasonic energy meter is 1 megahertz (1 million Hz / s), the direction is accurate, and the penetration is strong. Through the three major effects of sound waves (mechanical, warm, physical and chemical effects) on various parts of the human body, to achieve the role of massage relaxation.
Ultrasound Treatment, Healthcare Ultrasound, Medical Ultrasound, Therapeutic Ultrasound
Shenzhen Guangyang Zhongkang Technology Co., Ltd. , https://www.szlighttherapymachine.com